Tirzepatid (2) – Mounjaro®
Type 2 diabetes mellitus, aged ≥ 10 to ≤ 17 years
Characteristics
| Start date | 01.03.2026 |
|---|---|
| Resolution | 20.08.2026 – active procedure |
| INN | Tirzepatid |
| Brand name | Mounjaro® |
| Pharm. company | Lilly Deutschland GmbH |
| G-BA Procedure ID | D-1301 |
| Therapeutic area | Metabolic diseases |
| Reason for procedure | New therapeutic indication |
| Specialty | confidential reimbursement price |
Associated procedures
| Tirzepatid (2) | Mounjaro® | Lilly Deutschland GmbH | Type 2 diabetes mellitus, aged ≥ 10 to ≤ 17 years | n.d. | active procedure | |
| Tirzepatid (1) | Mounjaro® | Lilly Deutschland GmbH | Diabetes mellitus type 2 | 1,461,000–2,021,000 | 23% Hint for minor additional benefit |
<< List of all resolutions